MedTrace Logo

Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study

NCT05276323 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-03-11

No results posted yet for this study

Summary

A randomized, open-label trial comparing Medihoney Derma Cream to Hydrocortisone 1% cream. Children between the ages of 2-18 years old diagnosed with mild to moderate atopic dermatitis with an IGA (Investigator Global Assessment) score of 2-3, and a BSA (Body Surface Area) score of 1%-10% were included.

Conditions

Interventions

DRUG

Medihoney Derma Cream

applied topically, twice a day, on all affected areas in the body for two weeks.

DRUG

Hydrocortisone 1% cream

applied topically, twice a day, on all affected areas in the body for two weeks.

Sponsors & Collaborators

  • Soroka University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-02-28
Completion
2021-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05276323 on ClinicalTrials.gov